Please enable JavaScript to continue using this application.

Compare $LYEL vs $SION | Chartloom

Compare

$LYEL vs $SION

Lyell Immunopharma Inc · Sionna Therapeutics Inc

LYEL

Lyell Immunopharma Inc

SION

Sionna Therapeutics Inc

Compare $LYEL vs $SION

Comparing Lyell Immunopharma Inc and Sionna Therapeutics Inc

LYELLyell Immunopharma Inc

SIONSionna Therapeutics Inc

LYELLyell Immunopharma Inc

Market cap

$203M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

16,911.71x

Rev growth (TTM)

-55.0%

YTD performance

-69.9%

52W performance

-52.3%

FCF yield

-86.2%

SIONSionna Therapeutics Inc

Market cap

$221M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-87.5%

52W performance

-82.8%

FCF yield

-34.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LYEL

SION

Detailed metrics comparison

LYEL

Lyell Immunopharma Inc

SION

Sionna Therapeutics Inc

Market Cap

LYEL$203M

SION$221M

Enterprise Value

LYEL$130M

SION$158M

Price

LYEL$8.71

SION$4.90

P/E Ratio

LYELN/A

SIONN/A

P/S Ratio

LYEL7,526.09x

SION0.00x

EV/Sales

LYEL4,822.94x

SION0.00x

EV/EBITDA

LYEL0.00x

SION0.00x

P/B Ratio

LYEL0.97x

SION0.84x

P/FCF Ratio

LYELN/A

SIONN/A

EV/FCF

LYEL-0.74x

SION-2.07x

PEG Ratio

LYELN/A

SIONN/A

Forward P/E (NTM)

LYELN/A

SIONN/A

Forward P/S (NTM)

LYEL16,911.71x

SIONN/A

Revenue (TTM)

LYEL$27K

SION$0

Revenue Growth (YoY)

LYEL-55.0%

SIONN/A

Forward Rev Growth

LYEL7184.7%

SION1297.1%

Gross Margin (TTM)

LYEL0.0%

SION0.0%

Operating Margin (TTM)

LYEL0.0%

SION0.0%

EBITDA Margin (TTM)

LYEL-669059.3%

SION0.0%

Net Margin (TTM)

LYEL-920285.2%

SION0.0%

FCF Margin (TTM)

LYEL-648763.0%

SIONN/A

Net Income (TTM)

LYEL$-248M

SION$-97M

FCF (TTM)

LYEL$-175M

SION$-76M

EPS (TTM)

LYEL-$10.64

SION-$2.16

ROE (TTM)

LYEL-9162.0%

SION-3294.0%

ROA (TTM)

LYEL-7050.0%

SION-3108.0%

ROIC (TTM)

LYEL-9162.0%

SION-3294.0%

Cash

LYEL$73M

SION$63M

Debt

LYEL$0

SION$0

Net Cash/Debt

LYEL$73M

SION$63M

Current Ratio (TTM)

LYEL5.36x

SION20.05x

Quick Ratio (TTM)

LYEL5.12x

SION19.57x

Debt/Equity (TTM)

LYEL0.00x

SION0.00x

Debt/Assets (TTM)

LYEL0.0%

SION0.0%

Interest Coverage (TTM)

LYELN/A

SIONN/A

Net Debt/EBITDA (TTM)

LYEL0.00x

SION0.00x

Beta

LYEL-0.04

SION1.44

52W Performance

LYEL-52.3%

SION-82.8%

YTD Performance

LYEL-69.9%

SION-87.5%

% from 52W High

LYEL-80.6%

SION-91.1%

% from 52W Low

LYEL6.1%

SION22.2%

Asset Turnover (TTM)

LYEL0.00x

SION0.00x

FCF Yield (TTM)

LYEL-86.2%

SION-34.4%

Earnings Yield (TTM)

LYEL-122.3%

SION-44.0%

Dividend Yield (TTM)

LYELN/A

SIONN/A

Rule of 40

LYEL-648,818.0

SION0.0

EV/GP/RG

LYELN/A

SIONN/A

Ticker research

View LYEL research View SION research

Metric	LYEL Lyell Immunopharma Inc	SION Sionna Therapeutics Inc
Market & Valuation
Market Cap	$203M	$221M
Enterprise Value	$130M	$158M
Price	$8.71	$4.90
P/E Ratio	N/A	N/A
P/S Ratio	7,526.09x	0.00x
EV/Sales	4,822.94x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	0.84x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.74x	-2.07x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	16,911.71x	N/A
Revenue & Growth
Revenue (TTM)	$27K	$0
Revenue Growth (YoY)	-55.0%	N/A
Forward Rev Growth	7184.7%	1297.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-669059.3%	0.0%
Net Margin (TTM)	-920285.2%	0.0%
FCF Margin (TTM)	-648763.0%	N/A
Net Income (TTM)	$-248M	$-97M
FCF (TTM)	$-175M	$-76M
EPS (TTM)	-$10.64	-$2.16
ROE (TTM)	-9162.0%	-3294.0%
ROA (TTM)	-7050.0%	-3108.0%
ROIC (TTM)	-9162.0%	-3294.0%
Financial Health
Cash	$73M	$63M
Debt	$0	$0
Net Cash/Debt	$73M	$63M
Current Ratio (TTM)	5.36x	20.05x
Quick Ratio (TTM)	5.12x	19.57x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.04	1.44
52W Performance	-52.3%	-82.8%
YTD Performance	-69.9%	-87.5%
% from 52W High	-80.6%	-91.1%
% from 52W Low	6.1%	22.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-86.2%	-34.4%
Earnings Yield (TTM)	-122.3%	-44.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-648,818.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View LYEL research	View SION research

Valuation

P/S Ratio

SION

0.00x

LYEL

7,526.09x

EV/FCF

SION

-2.07x

LYEL

-0.74x

Growth & revenue

Revenue Growth TTM

LYEL

-55.0%

Forward Revenue Growth

LYEL

7184.7%

SION

1297.1%

Profitability & performance

Gross Margin

LYEL

0.0%

SION

0.0%

ROE

SION

-3294.0%

LYEL

-9162.0%

FCF Yield %

SION

-34.4%

LYEL

-86.2%

52-Week Performance

LYEL

-52.3%

SION

-82.8%

Detailed metrics comparison

LYEL

Lyell Immunopharma Inc

SION

Sionna Therapeutics Inc

Market Cap

LYEL$203M

SION$221M

Enterprise Value

LYEL$130M

SION$158M

Price

LYEL$8.71

SION$4.90

P/E Ratio

LYELN/A

SIONN/A

P/S Ratio

LYEL7,526.09x

SION0.00x

EV/Sales

LYEL4,822.94x

SION0.00x

EV/EBITDA

LYEL0.00x

SION0.00x

P/B Ratio

LYEL0.97x

SION0.84x

P/FCF Ratio

LYELN/A

SIONN/A

EV/FCF

LYEL-0.74x

SION-2.07x

PEG Ratio

LYELN/A

SIONN/A

Forward P/E (NTM)

LYELN/A

SIONN/A

Forward P/S (NTM)

LYEL16,911.71x

SIONN/A

Revenue (TTM)

LYEL$27K

SION$0

Revenue Growth (YoY)

LYEL-55.0%

SIONN/A

Forward Rev Growth

LYEL7184.7%

SION1297.1%

Gross Margin (TTM)

LYEL0.0%

SION0.0%

Operating Margin (TTM)

LYEL0.0%

SION0.0%

EBITDA Margin (TTM)

LYEL-669059.3%

SION0.0%

Net Margin (TTM)

LYEL-920285.2%

SION0.0%

FCF Margin (TTM)

LYEL-648763.0%

SIONN/A

Net Income (TTM)

LYEL$-248M

SION$-97M

FCF (TTM)

LYEL$-175M

SION$-76M

EPS (TTM)

LYEL-$10.64

SION-$2.16

ROE (TTM)

LYEL-9162.0%

SION-3294.0%

ROA (TTM)

LYEL-7050.0%

SION-3108.0%

ROIC (TTM)

LYEL-9162.0%

SION-3294.0%

Cash

LYEL$73M

SION$63M

Debt

LYEL$0

SION$0

Net Cash/Debt

LYEL$73M

SION$63M

Current Ratio (TTM)

LYEL5.36x

SION20.05x

Quick Ratio (TTM)

LYEL5.12x

SION19.57x

Debt/Equity (TTM)

LYEL0.00x

SION0.00x

Debt/Assets (TTM)

LYEL0.0%

SION0.0%

Interest Coverage (TTM)

LYELN/A

SIONN/A

Net Debt/EBITDA (TTM)

LYEL0.00x

SION0.00x

Beta

LYEL-0.04

SION1.44

52W Performance

LYEL-52.3%

SION-82.8%

YTD Performance

LYEL-69.9%

SION-87.5%

% from 52W High

LYEL-80.6%

SION-91.1%

% from 52W Low

LYEL6.1%

SION22.2%

Asset Turnover (TTM)

LYEL0.00x

SION0.00x

FCF Yield (TTM)

LYEL-86.2%

SION-34.4%

Earnings Yield (TTM)

LYEL-122.3%

SION-44.0%

Dividend Yield (TTM)

LYELN/A

SIONN/A

Rule of 40

LYEL-648,818.0

SION0.0

EV/GP/RG

LYELN/A

SIONN/A

Ticker research

View LYEL research View SION research

Metric	LYEL Lyell Immunopharma Inc	SION Sionna Therapeutics Inc
Market & Valuation
Market Cap	$203M	$221M
Enterprise Value	$130M	$158M
Price	$8.71	$4.90
P/E Ratio	N/A	N/A
P/S Ratio	7,526.09x	0.00x
EV/Sales	4,822.94x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	0.84x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.74x	-2.07x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	16,911.71x	N/A
Revenue & Growth
Revenue (TTM)	$27K	$0
Revenue Growth (YoY)	-55.0%	N/A
Forward Rev Growth	7184.7%	1297.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-669059.3%	0.0%
Net Margin (TTM)	-920285.2%	0.0%
FCF Margin (TTM)	-648763.0%	N/A
Net Income (TTM)	$-248M	$-97M
FCF (TTM)	$-175M	$-76M
EPS (TTM)	-$10.64	-$2.16
ROE (TTM)	-9162.0%	-3294.0%
ROA (TTM)	-7050.0%	-3108.0%
ROIC (TTM)	-9162.0%	-3294.0%
Financial Health
Cash	$73M	$63M
Debt	$0	$0
Net Cash/Debt	$73M	$63M
Current Ratio (TTM)	5.36x	20.05x
Quick Ratio (TTM)	5.12x	19.57x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.04	1.44
52W Performance	-52.3%	-82.8%
YTD Performance	-69.9%	-87.5%
% from 52W High	-80.6%	-91.1%
% from 52W Low	6.1%	22.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-86.2%	-34.4%
Earnings Yield (TTM)	-122.3%	-44.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-648,818.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View LYEL research	View SION research